Nilotinib

From Wikipedia, the free encyclopedia

Nilotinib
Systematic (IUPAC) name
4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)
phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]
benzamide
Identifiers
CAS number  ?
ATC code  ?
PubChem 644241
Chemical data
Formula C28H22F3N7O 
Mol. mass 529.516 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes Oral

Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec®), another tyrosine kinase inhibitor currently used as a first-line treatment.[1] In that study 92% of patients (already resistant or unresponsive to Gleevec) achieved a normal white blood cell counts after 5 month of treatment. [2]

[edit] References

  1. ^ Kantarjian H et al. (2006). "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL". N Engl J Med 354 (24): 2542-51. PMID 16775235. 
  2. ^ http://cws.huginonline.com/N/134323/PR/200606/1056533_5.html Patients with treatment-resistant leukemia achieve high responses to Tasigna® (nilotinib) in first published clinical trial results - Novartis 14/06/2006 Press Release.